We sought to evaluate the MICRONAUT MIC-Strip colistin (MMS) assay, a commercial broth microdilution (BMD) panel, using 273 carbapenem-resistant Acinetobacter baumannii and Enterobacterales isolates. BMD was used as gold standard. MMS had 98.5% sensitivity and 99.5% specificity. All 37 isolates with MICs close to the breakpoint exhibited complete agreement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diagmicrobio.2021.115391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of : Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest.
Antibiotics (Basel)
September 2024
Department of Microbiology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait.
Article Synopsis
- Recent outbreaks of multidrug-resistant fungi in healthcare settings highlight the need for effective antifungal susceptibility testing (AST) to manage invasive infections.* -
- The study compared the performance of Etest and broth microdilution-based MICRONAUT-AM-EUCAST assays by testing 121 clinical isolates, revealing significant discrepancies in fluconazole and amphotericin B resistance assessments.* -
- Findings suggest that MCN-AM underestimates fluconazole resistance, while Etest overestimates amphotericin B resistance, indicating a need for method-specific resistance breakpoints to improve clinical outcomes.*
Two-site study on performances of a commercially available MALDI-TOF MS-based assay for the detection of colistin resistance in Escherichia coli.
Eur J Clin Microbiol Infect Dis
June 2023
Bruker Daltonics GmbH & Co KG, Bremen, Germany.
Colistin is a last resort drug for the treatment of multiple drug-resistant (MDR) Gram-negative bacterial infections. Rapid methods to detect resistance are highly desirable. Here, we evaluated the performance of a commercially available MALDI-TOF MS-based assay for colistin resistance testing in Escherichia coli at two different sites.
View Article and Find Full Text PDFComparison of Six Phenotypic Assays with Reference Methods for Assessing Colistin Resistance in Clinical Isolates of Carbapenemase-Producing Enterobacterales: Challenges and Opportunities.
Antibiotics (Basel)
March 2022
Department of Clinical Biochemistry, Central Clinical Laboratory, County Emergency Clinical Hospital, 540136 Targu Mures, Romania.
The global escalation of severe infections due to carbapenemase-producing Enterobacterales (CPE) isolates has prompted increased usage of parenteral colistin. Considering the reported difficulties in assessing their susceptibility to colistin, the purpose of the study was to perform a comparative evaluation of six phenotypic assays-the colistin broth disc elution (CBDE), Vitek 2 Compact (bioMérieux SA, Marcy l'Etoile, France), the Micronaut MIC-Strip Colistin (Merlin Diagnostika GMBH, Bornheim-Hensel, Germany), the gradient diffusion strip Etest (bioMérieux SA, Marcy l'Etoile, France), ChromID Colistin R Agar (COLR) (bioMérieux SA, Marcy l'Etoile, France), and the Rapid Polymyxin NP Test (ELITechGroup, Signes, France)-versus the reference method of broth microdilution (BMD). All false resistance results were further assessed using population analysis profiling (PAP).
View Article and Find Full Text PDFCurrent and emerging polymyxin resistance diagnostics: A systematic review of established and novel detection methods.
J Appl Microbiol
January 2022
Department of Medical Microbiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
The emergence of polymyxin resistance, due to transferable mcr genes, threatens public and animal health as there are limited therapeutic options. As polymyxin is one of the last-line antibiotics, there is a need to contain the spread of its resistance to conserve its efficacy. Herein, we describe current and emerging polymyxin resistance diagnostics to inform faster clinical diagnostic choices.
View Article and Find Full Text PDFEvaluation of the MICRONAUT MIC-strip colistin assay for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii and Enterobacterales.
Diagn Microbiol Infect Dis
August 2021
National Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Israel. Electronic address:
We sought to evaluate the MICRONAUT MIC-Strip colistin (MMS) assay, a commercial broth microdilution (BMD) panel, using 273 carbapenem-resistant Acinetobacter baumannii and Enterobacterales isolates. BMD was used as gold standard. MMS had 98.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!